InflaRx NV【IFRX】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.29

買値

2.36

売値

2.45

出来高

0.00 日の範囲 0.00

1.165 52 週間の範囲 2.815

時価総額

134.843M

前日終値

2.29

始値

時刻

2.36

最終取引時間

22:43:38

財務取引量

VWAP

平均取引量 (3 か月)

290,622

発行済株式数

58,883,272

配当利回り

PER

-3.16

1 株当たり利益 (EPS)

-0.72

歳入

63k

純利益

-42.67M

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.inflarx.de

本社

Jena, Deu

設立

InflaRx NV is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker IFRX. The last closing price for InflaRx NV was US$2.29. Over the last year, InflaRx NV shares have traded in a share price range of US$ 1.165 to US$ 2.815.

InflaRx NV currently has 58,883,272 shares in issue. The market capitalisation of InflaRx NV is US$134.84 million. InflaRx NV has a price to earnings ratio (PE ratio) of -3.16.

InflaRx Announces Participation in January Events in San Francisco

JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

JENA, Germany, Nov. 15, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable interim analysis, with guidance for trial size adaptation or futility expected by the...

InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.38	-14.2322097378	2.67	2.67	2.23	192934	2.37958083	CS
4	-0.28	-10.8949416342	2.57	2.76	1.9323	268556	2.38464503	CS
12	0.8	53.6912751678	1.49	2.815	1.43	290622	2.15134146	CS
26	0.69	43.125	1.6	2.815	1.23	164375	2.02565659	CS
52	0.49	27.2222222222	1.8	2.815	1.165	184471	1.77649565	CS
156	-1.95	-45.9905660377	4.24	7.2499	0.7762	413939	3.75077249	CS
260	-1.27	-35.6741573034	3.56	9.7	0.7762	591485	4.2383488	CS

IFRX - Frequently Asked Questions (FAQ)

What is the current InflaRx NV share price?

The current share price of InflaRx NV is US$ 2.29

How many InflaRx NV shares are in issue?

InflaRx NV has 58,883,272 shares in issue

What is the market cap of InflaRx NV?

The market capitalisation of InflaRx NV is USD 134.84M

What is the 1 year trading range for InflaRx NV share price?

InflaRx NV has traded in the range of US$ 1.165 to US$ 2.815 during the past year

What is the PE ratio of InflaRx NV?

The price to earnings ratio of InflaRx NV is -3.16

What is the cash to sales ratio of InflaRx NV?

The cash to sales ratio of InflaRx NV is 2.08k

What is the reporting currency for InflaRx NV?

InflaRx NV reports financial results in EUR

What is the latest annual turnover for InflaRx NV?

The latest annual turnover of InflaRx NV is EUR 63k

What is the latest annual profit for InflaRx NV?

The latest annual profit of InflaRx NV is EUR -42.67M

What is the registered address of InflaRx NV?

The registered address for InflaRx NV is WINZERLAER, JENA, 07745

What is the InflaRx NV website address?

The website address for InflaRx NV is www.inflarx.de

Which industry sector does InflaRx NV operate in?

InflaRx NV operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
XTIAXTI Aerospace Inc	US$ 0.2094 (137.95%)	602.57M
HOTHHoth Therapeutics Inc	US$ 1.62 (97.66%)	20.82M
IMRXImmuneering Corporation	US$ 4.39 (86.02%)	42.53M
MSAIMultiSensor AI Holdings Inc	US$ 3.40 (70.00%)	38.19M
RIMEAlgorhythm Holdings Inc	US$ 0.235 (62.29%)	173.71M
LFWDLifeward Ltd	US$ 1.84 (-39.47%)	526.42k
SLRNACELYRIN Inc	US$ 2.30 (-34.10%)	592.37k
BOXLBoxlight Corporation	US$ 1.22 (-27.38%)	1.8M
AMSTAmesite Inc	US$ 3.00 (-25.93%)	67.56k
DHAIDIH Holdings US Inc	US$ 2.25 (-22.95%)	156.07k
XTIAXTI Aerospace Inc	US$ 0.2092 (137.73%)	602.68M
RIMEAlgorhythm Holdings Inc	US$ 0.2347 (62.09%)	173.72M
SVMHSRIVARU Holding Ltd	US$ 0.0671 (44.92%)	121.36M
CDTConduit Pharmaceuticals Inc	US$ 0.1099 (52.01%)	74.4M
CEROCERo Therapeutics Holdings Inc	US$ 0.05785 (36.76%)	61.25M